Takeda Launches CDPATH™, a Personalized Prognostic To

/PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) today announced the national launch of the CDPATH™ program, which includes an innovative, validated personalized...

Related Keywords

United States , Japan , Cambridge , Cambridgeshire , United Kingdom , Japanese , America , Prnewswire Takeda , Amy Mccarthy , J Gastroenterol Hepatol , Mike Walther , Corey Siegel , Jun Saito , National Institute Of Diabetes , Department Of Defense , Mitest Health , Takeda Pharmaceutical Company , Takeda Pharmaceuticals , Dartmouth Hitchcock Medical Center , Takeda Pharmaceuticals United Statesa Inc , Takeda Pharmaceutical Company Limited , York State Department Of Health , Mitest Co , Colitis Foundation , National Institutes Of Health , Prometheus Laboratories Inc , Patient Service Centers , Department Of Veteran Affairs , Exchange Commission , Public Health Service , Clinical Laboratory Improvement Amendments , Laboratory Developed Test , Our Gi Research Development , Quest Diagnostics , Multichannel News Release , Gastroenterology Business Unit , Takeda Pharmaceuticals United Statesa , Prometheus Laboratories , Atest Health , New York State Department , Mitest Co Founder , Section Chief , Dartmouth Hitchcock Medical , Coast Guard , North America , Rare Genetics , Plasma Derived Therapies , Annual Report , Inflammatory Bowel Disease , Irritable Bowel Syndrome , National Institutes , National Institute , Accessed March , Pharmaceutical Company ,